Article
ErbB-2 nuclear function in breast cancer growth, metastasis and resistance to therapy
7 Oct 2016
Abstract excerpt
Approximately 15-20% of breast cancers (BC) show either membrane overexpression of ErbB-2 (MErbB-2), a member of the ErbBs family of receptor tyrosine kinases, or ERBB2 gene amplification. Until the development of MErbB-2-targeted therapies, this BC subtype, called ErbB-2-positive, was associated with increased metastatic potential and poor prognosis. Although these therapies have significantly improved overall...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
